Antiproliferative drugs are the type of immunosuppressive medication that works by blocking cell-cycle pathways, limiting the T- and B-cell proliferation and thereby lowering the cytotoxic response aimed at the cardiac allograft. It is also termed as antimetabolites. Immunosuppressants are a type of medication that helps to suppress the immune system's response to foreign substances. These medications limit the immune response and safeguard the new organ and its function, prevent organ rejection. They're most commonly used to prevent autoimmune illnesses such as arthritis, myasthenia gravis, Crohn's disease, lupus, rheumatoid arthritis, and organ transplant rejections like kidney, liver, and heart transplants.

The latest research study released by Market IntelliX evaluates market size and forecasts of Antiproliferative Drugs in Global, including the following market information:

Global Antiproliferative Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Antiproliferative Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Mycophenolate Mofetil Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Antiproliferative Drugs include Accord Healthcare, F. Hoffmann-La Roche, Novartis AG, Mylan N.V., Astellas Pharma, Pfizer, Glenmark Pharmaceuticals Limited, Zydus Cadila and Bristol-Myers Squibb Company, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MI has surveyed the Antiproliferative Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Market Segmentations:

Global Antiproliferative Drugs Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Antiproliferative Drugs Market Segment Percentages, by Type, 2021 (%)

Mycophenolate Mofetil

Mycophenolate Sodium

Azathioprine

Global Antiproliferative Drugs Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Antiproliferative Drugs Market Segment Percentages, by Application, 2021 (%)

Clinic

Hospital

Others

Global Antiproliferative Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Antiproliferative Drugs Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Antiproliferative Drugs revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Antiproliferative Drugs revenues share in global market, 2021 (%)

The report presents profiles of competitors in the market, Some of the prominent key players covered:

Accord Healthcare

F. Hoffmann-La Roche

Novartis AG

Mylan N.V.

Astellas Pharma

Pfizer

Glenmark Pharmaceuticals Limited

Zydus Cadila

Bristol-Myers Squibb Company

GlaxoSmithKline

Sanofi

Allergan

AbbVie

Cipla

Johnson & Johnson Private Limited

Teva Pharmaceutical Industries

Veloxis Pharmaceuticals

Eli Lilly and Company

Lupin

AstraZeneca

Key Takeaways from this Report

Evaluate market potential through analyzing growth rates (CAGR %), Volume (Units) and Value ($M) data given at country level – for product types, end use applications and by different industry verticals.

Understand the different dynamics influencing the market – key driving factors, challenges and hidden opportunities.

Get in-depth insights on your competitor performance – market shares, strategies, financial benchmarking, product benchmarking, SWOT and more.

Analyze the sales and distribution channels across key geographies to improve top-line revenues.

Understand the industry supply chain with a deep-dive on the value augmentation at each step, in order to optimize value and bring efficiencies in your processes.

Get a quick outlook on the market entropy – M&A’s, deals, partnerships, product launches of all key players for the past 4 years.

Evaluate the supply-demand gaps, import-export statistics and regulatory landscape for more than top 20 countries globally for the market.

1 Introduction to Research & Analysis Reports

1.1 Antiproliferative Drugs Market Definition

1.2 Market Segments

1.2.1 Market by Type

1.2.2 Market by Application

1.3 Global Antiproliferative Drugs Market Overview

1.4 Features & Benefits of This Report

1.5 Methodology & Sources of Information

1.5.1 Research Methodology

1.5.2 Research Process

1.5.3 Base Year

1.5.4 Report Assumptions & Caveats

2 Global Antiproliferative Drugs Overall Market Size

2.1 Global Antiproliferative Drugs Market Size: 2021 VS 2028

2.2 Global Antiproliferative Drugs Market Size, Prospects & Forecasts: 2017-2028

2.3 Key Market Trends, Opportunity, Drivers and Restraints

2.3.1 Market Opportunities & Trends

2.3.2 Market Drivers

2.3.3 Market Restraints

3 Company Landscape

3.1 Top Antiproliferative Drugs Players in Global Market

3.2 Top Global Antiproliferative Drugs Companies Ranked by Revenue

3.3 Global Antiproliferative Drugs Revenue by Companies

3.4 Top 3 and Top 5 Antiproliferative Drugs Companies in Global Market, by Revenue in 2021

3.5 Global Companies Antiproliferative Drugs Product Type

3.6 Tier 1, Tier 2 and Tier 3 Antiproliferative Drugs Players in Global Market

3.6.1 List of Global Tier 1 Antiproliferative Drugs Companies

3.6.2 List of Global Tier 2 and Tier 3 Antiproliferative Drugs Companies

4 Market Sights by Product

4.1 Overview

4.1.1 by Type - Global Antiproliferative Drugs Market Size Markets, 2021 & 2028

4.1.2 Mycophenolate Mofetil

4.1.3 Mycophenolate Sodium

4.1.4 Azathioprine

4.2 By Type - Global Antiproliferative Drugs Revenue & Forecasts

4.2.1 By Type - Global Antiproliferative Drugs Revenue, 2017-2022

4.2.2 By Type - Global Antiproliferative Drugs Revenue, 2023-2028

4.2.3 By Type - Global Antiproliferative Drugs Revenue Market Share, 2017-2028

5 Sights by Application

5.1 Overview

5.1.1 By Application - Global Antiproliferative Drugs Market Size, 2021 & 2028

5.1.2 Clinic

5.1.3 Hospital

5.1.4 Others

5.2 By Application - Global Antiproliferative Drugs Revenue & Forecasts

5.2.1 By Application - Global Antiproliferative Drugs Revenue, 2017-2022

5.2.2 By Application - Global Antiproliferative Drugs Revenue, 2023-2028

5.2.3 By Application - Global Antiproliferative Drugs Revenue Market Share, 2017-2028

6 Sights by Region

6.1 By Region - Global Antiproliferative Drugs Market Size, 2021 & 2028

6.2 By Region - Global Antiproliferative Drugs Revenue & Forecasts

6.2.1 By Region - Global Antiproliferative Drugs Revenue, 2017-2022

6.2.2 By Region - Global Antiproliferative Drugs Revenue, 2023-2028

6.2.3 By Region - Global Antiproliferative Drugs Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Antiproliferative Drugs Revenue, 2017-2028

6.3.2 US Antiproliferative Drugs Market Size, 2017-2028

6.3.3 Canada Antiproliferative Drugs Market Size, 2017-2028

6.3.4 Mexico Antiproliferative Drugs Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Antiproliferative Drugs Revenue, 2017-2028

6.4.2 Germany Antiproliferative Drugs Market Size, 2017-2028

6.4.3 France Antiproliferative Drugs Market Size, 2017-2028

6.4.4 U.K. Antiproliferative Drugs Market Size, 2017-2028

6.4.5 Italy Antiproliferative Drugs Market Size, 2017-2028

6.4.6 Russia Antiproliferative Drugs Market Size, 2017-2028

6.4.7 Nordic Countries Antiproliferative Drugs Market Size, 2017-2028

6.4.8 Benelux Antiproliferative Drugs Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia Antiproliferative Drugs Revenue, 2017-2028

6.5.2 China Antiproliferative Drugs Market Size, 2017-2028

6.5.3 Japan Antiproliferative Drugs Market Size, 2017-2028

6.5.4 South Korea Antiproliferative Drugs Market Size, 2017-2028

6.5.5 Southeast Asia Antiproliferative Drugs Market Size, 2017-2028

6.5.6 India Antiproliferative Drugs Market Size, 2017-2028

6.6 South America

6.6.1 By Country - South America Antiproliferative Drugs Revenue, 2017-2028

6.6.2 Brazil Antiproliferative Drugs Market Size, 2017-2028

6.6.3 Argentina Antiproliferative Drugs Market Size, 2017-2028

6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Antiproliferative Drugs Revenue, 2017-2028

6.7.2 Turkey Antiproliferative Drugs Market Size, 2017-2028

6.7.3 Israel Antiproliferative Drugs Market Size, 2017-2028

6.7.4 Saudi Arabia Antiproliferative Drugs Market Size, 2017-2028

6.7.5 UAE Antiproliferative Drugs Market Size, 2017-2028

7 Players Profiles

7.1 Accord Healthcare

7.1.1 Accord Healthcare Corporate Summary

7.1.2 Accord Healthcare Business Overview

7.1.3 Accord Healthcare Antiproliferative Drugs Major Product Offerings

7.1.4 Accord Healthcare Antiproliferative Drugs Revenue in Global Market (2017-2022)

7.1.5 Accord Healthcare Key News

7.2 F. Hoffmann-La Roche

7.2.1 F. Hoffmann-La Roche Corporate Summary

7.2.2 F. Hoffmann-La Roche Business Overview

7.2.3 F. Hoffmann-La Roche Antiproliferative Drugs Major Product Offerings

7.2.4 F. Hoffmann-La Roche Antiproliferative Drugs Revenue in Global Market (2017-2022)

7.2.5 F. Hoffmann-La Roche Key News

7.3 Novartis AG

7.3.1 Novartis AG Corporate Summary

7.3.2 Novartis AG Business Overview

7.3.3 Novartis AG Antiproliferative Drugs Major Product Offerings

7.3.4 Novartis AG Antiproliferative Drugs Revenue in Global Market (2017-2022)

7.3.5 Novartis AG Key News

7.4 Mylan N.V.

7.4.1 Mylan N.V. Corporate Summary

7.4.2 Mylan N.V. Business Overview

7.4.3 Mylan N.V. Antiproliferative Drugs Major Product Offerings

7.4.4 Mylan N.V. Antiproliferative Drugs Revenue in Global Market (2017-2022)

7.4.5 Mylan N.V. Key News

7.5 Astellas Pharma

7.5.1 Astellas Pharma Corporate Summary

7.5.2 Astellas Pharma Business Overview

7.5.3 Astellas Pharma Antiproliferative Drugs Major Product Offerings

7.5.4 Astellas Pharma Antiproliferative Drugs Revenue in Global Market (2017-2022)

7.5.5 Astellas Pharma Key News

7.6 Pfizer

7.6.1 Pfizer Corporate Summary

7.6.2 Pfizer Business Overview

7.6.3 Pfizer Antiproliferative Drugs Major Product Offerings

7.6.4 Pfizer Antiproliferative Drugs Revenue in Global Market (2017-2022)

7.6.5 Pfizer Key News

7.7 Glenmark Pharmaceuticals Limited

7.7.1 Glenmark Pharmaceuticals Limited Corporate Summary

7.7.2 Glenmark Pharmaceuticals Limited Business Overview

7.7.3 Glenmark Pharmaceuticals Limited Antiproliferative Drugs Major Product Offerings

7.7.4 Glenmark Pharmaceuticals Limited Antiproliferative Drugs Revenue in Global Market (2017-2022)

7.7.5 Glenmark Pharmaceuticals Limited Key News

7.8 Zydus Cadila

7.8.1 Zydus Cadila Corporate Summary

7.8.2 Zydus Cadila Business Overview

7.8.3 Zydus Cadila Antiproliferative Drugs Major Product Offerings

7.8.4 Zydus Cadila Antiproliferative Drugs Revenue in Global Market (2017-2022)

7.8.5 Zydus Cadila Key News

7.9 Bristol-Myers Squibb Company

7.9.1 Bristol-Myers Squibb Company Corporate Summary

7.9.2 Bristol-Myers Squibb Company Business Overview

7.9.3 Bristol-Myers Squibb Company Antiproliferative Drugs Major Product Offerings

7.9.4 Bristol-Myers Squibb Company Antiproliferative Drugs Revenue in Global Market (2017-2022)

7.9.5 Bristol-Myers Squibb Company Key News

7.10 GlaxoSmithKline

7.10.1 GlaxoSmithKline Corporate Summary

7.10.2 GlaxoSmithKline Business Overview

7.10.3 GlaxoSmithKline Antiproliferative Drugs Major Product Offerings

7.10.4 GlaxoSmithKline Antiproliferative Drugs Revenue in Global Market (2017-2022)

7.10.5 GlaxoSmithKline Key News

7.11 Sanofi

7.11.1 Sanofi Corporate Summary

7.11.2 Sanofi Business Overview

7.11.3 Sanofi Antiproliferative Drugs Major Product Offerings

7.11.4 Sanofi Antiproliferative Drugs Revenue in Global Market (2017-2022)

7.11.5 Sanofi Key News

7.12 Allergan

7.12.1 Allergan Corporate Summary

7.12.2 Allergan Business Overview

7.12.3 Allergan Antiproliferative Drugs Major Product Offerings

7.12.4 Allergan Antiproliferative Drugs Revenue in Global Market (2017-2022)

7.12.5 Allergan Key News

7.13 AbbVie

7.13.1 AbbVie Corporate Summary

7.13.2 AbbVie Business Overview

7.13.3 AbbVie Antiproliferative Drugs Major Product Offerings

7.13.4 AbbVie Antiproliferative Drugs Revenue in Global Market (2017-2022)

7.13.5 AbbVie Key News

7.14 Cipla

7.14.1 Cipla Corporate Summary

7.14.2 Cipla Business Overview

7.14.3 Cipla Antiproliferative Drugs Major Product Offerings

7.14.4 Cipla Antiproliferative Drugs Revenue in Global Market (2017-2022)

7.14.5 Cipla Key News

7.15 Johnson & Johnson Private Limited

7.15.1 Johnson & Johnson Private Limited Corporate Summary

7.15.2 Johnson & Johnson Private Limited Business Overview

7.15.3 Johnson & Johnson Private Limited Antiproliferative Drugs Major Product Offerings

7.15.4 Johnson & Johnson Private Limited Antiproliferative Drugs Revenue in Global Market (2017-2022)

7.15.5 Johnson & Johnson Private Limited Key News

7.16 Teva Pharmaceutical Industries

7.16.1 Teva Pharmaceutical Industries Corporate Summary

7.16.2 Teva Pharmaceutical Industries Business Overview

7.16.3 Teva Pharmaceutical Industries Antiproliferative Drugs Major Product Offerings

7.16.4 Teva Pharmaceutical Industries Antiproliferative Drugs Revenue in Global Market (2017-2022)

7.16.5 Teva Pharmaceutical Industries Key News

7.17 Veloxis Pharmaceuticals

7.17.1 Veloxis Pharmaceuticals Corporate Summary

7.17.2 Veloxis Pharmaceuticals Business Overview

7.17.3 Veloxis Pharmaceuticals Antiproliferative Drugs Major Product Offerings

7.17.4 Veloxis Pharmaceuticals Antiproliferative Drugs Revenue in Global Market (2017-2022)

7.17.5 Veloxis Pharmaceuticals Key News

7.18 Eli Lilly and Company

7.18.1 Eli Lilly and Company Corporate Summary

7.18.2 Eli Lilly and Company Business Overview

7.18.3 Eli Lilly and Company Antiproliferative Drugs Major Product Offerings

7.18.4 Eli Lilly and Company Antiproliferative Drugs Revenue in Global Market (2017-2022)

7.18.5 Eli Lilly and Company Key News

7.19 Lupin

7.19.1 Lupin Corporate Summary

7.19.2 Lupin Business Overview

7.19.3 Lupin Antiproliferative Drugs Major Product Offerings

7.19.4 Lupin Antiproliferative Drugs Revenue in Global Market (2017-2022)

7.19.5 Lupin Key News

7.20 AstraZeneca

7.20.1 AstraZeneca Corporate Summary

7.20.2 AstraZeneca Business Overview

7.20.3 AstraZeneca Antiproliferative Drugs Major Product Offerings

7.20.4 AstraZeneca Antiproliferative Drugs Revenue in Global Market (2017-2022)

7.20.5 AstraZeneca Key News

8 Conclusion

9 Appendix

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

List of Tables

Table 1. Antiproliferative Drugs Market Opportunities & Trends in Global Market

Table 2. Antiproliferative Drugs Market Drivers in Global Market

Table 3. Antiproliferative Drugs Market Restraints in Global Market

Table 4. Key Players of Antiproliferative Drugs in Global Market

Table 5. Top Antiproliferative Drugs Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Antiproliferative Drugs Revenue by Companies, (US$, Mn), 2017-2022

Table 7. Global Antiproliferative Drugs Revenue Share by Companies, 2017-2022

Table 8. Global Companies Antiproliferative Drugs Product Type

Table 9. List of Global Tier 1 Antiproliferative Drugs Companies, Revenue (US$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Antiproliferative Drugs Companies, Revenue (US$, Mn) in 2021 and Market Share

Table 11. By Type – Global Antiproliferative Drugs Revenue, (US$, Mn), 2021 & 2028

Table 12. By Type - Antiproliferative Drugs Revenue in Global (US$, Mn), 2017-2022

Table 13. By Type - Antiproliferative Drugs Revenue in Global (US$, Mn), 2023-2028

Table 14. By Application – Global Antiproliferative Drugs Revenue, (US$, Mn), 2021 & 2028

Table 15. By Application - Antiproliferative Drugs Revenue in Global (US$, Mn), 2017-2022

Table 16. By Application - Antiproliferative Drugs Revenue in Global (US$, Mn), 2023-2028

Table 17. By Region – Global Antiproliferative Drugs Revenue, (US$, Mn), 2021 & 2028

Table 18. By Region - Global Antiproliferative Drugs Revenue (US$, Mn), 2017-2022

Table 19. By Region - Global Antiproliferative Drugs Revenue (US$, Mn), 2023-2028

Table 20. By Country - North America Antiproliferative Drugs Revenue, (US$, Mn), 2017-2022

Table 21. By Country - North America Antiproliferative Drugs Revenue, (US$, Mn), 2023-2028

Table 22. By Country - Europe Antiproliferative Drugs Revenue, (US$, Mn), 2017-2022

Table 23. By Country - Europe Antiproliferative Drugs Revenue, (US$, Mn), 2023-2028

Table 24. By Region - Asia Antiproliferative Drugs Revenue, (US$, Mn), 2017-2022

Table 25. By Region - Asia Antiproliferative Drugs Revenue, (US$, Mn), 2023-2028

Table 26. By Country - South America Antiproliferative Drugs Revenue, (US$, Mn), 2017-2022

Table 27. By Country - South America Antiproliferative Drugs Revenue, (US$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Antiproliferative Drugs Revenue, (US$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Antiproliferative Drugs Revenue, (US$, Mn), 2023-2028

Table 30. Accord Healthcare Corporate Summary

Table 31. Accord Healthcare Antiproliferative Drugs Product Offerings

Table 32. Accord Healthcare Antiproliferative Drugs Revenue (US$, Mn), (2017-2022)

Table 33. F. Hoffmann-La Roche Corporate Summary

Table 34. F. Hoffmann-La Roche Antiproliferative Drugs Product Offerings

Table 35. F. Hoffmann-La Roche Antiproliferative Drugs Revenue (US$, Mn), (2017-2022)

Table 36. Novartis AG Corporate Summary

Table 37. Novartis AG Antiproliferative Drugs Product Offerings

Table 38. Novartis AG Antiproliferative Drugs Revenue (US$, Mn), (2017-2022)

Table 39. Mylan N.V. Corporate Summary

Table 40. Mylan N.V. Antiproliferative Drugs Product Offerings

Table 41. Mylan N.V. Antiproliferative Drugs Revenue (US$, Mn), (2017-2022)

Table 42. Astellas Pharma Corporate Summary

Table 43. Astellas Pharma Antiproliferative Drugs Product Offerings

Table 44. Astellas Pharma Antiproliferative Drugs Revenue (US$, Mn), (2017-2022)

Table 45. Pfizer Corporate Summary

Table 46. Pfizer Antiproliferative Drugs Product Offerings

Table 47. Pfizer Antiproliferative Drugs Revenue (US$, Mn), (2017-2022)

Table 48. Glenmark Pharmaceuticals Limited Corporate Summary

Table 49. Glenmark Pharmaceuticals Limited Antiproliferative Drugs Product Offerings

Table 50. Glenmark Pharmaceuticals Limited Antiproliferative Drugs Revenue (US$, Mn), (2017-2022)

Table 51. Zydus Cadila Corporate Summary

Table 52. Zydus Cadila Antiproliferative Drugs Product Offerings

Table 53. Zydus Cadila Antiproliferative Drugs Revenue (US$, Mn), (2017-2022)

Table 54. Bristol-Myers Squibb Company Corporate Summary

Table 55. Bristol-Myers Squibb Company Antiproliferative Drugs Product Offerings

Table 56. Bristol-Myers Squibb Company Antiproliferative Drugs Revenue (US$, Mn), (2017-2022)

Table 57. GlaxoSmithKline Corporate Summary

Table 58. GlaxoSmithKline Antiproliferative Drugs Product Offerings

Table 59. GlaxoSmithKline Antiproliferative Drugs Revenue (US$, Mn), (2017-2022)

Table 60. Sanofi Corporate Summary

Table 61. Sanofi Antiproliferative Drugs Product Offerings

Table 62. Sanofi Antiproliferative Drugs Revenue (US$, Mn), (2017-2022)

Table 63. Allergan Corporate Summary

Table 64. Allergan Antiproliferative Drugs Product Offerings

Table 65. Allergan Antiproliferative Drugs Revenue (US$, Mn), (2017-2022)

Table 66. AbbVie Corporate Summary

Table 67. AbbVie Antiproliferative Drugs Product Offerings

Table 68. AbbVie Antiproliferative Drugs Revenue (US$, Mn), (2017-2022)

Table 69. Cipla Corporate Summary

Table 70. Cipla Antiproliferative Drugs Product Offerings

Table 71. Cipla Antiproliferative Drugs Revenue (US$, Mn), (2017-2022)

Table 72. Johnson & Johnson Private Limited Corporate Summary

Table 73. Johnson & Johnson Private Limited Antiproliferative Drugs Product Offerings

Table 74. Johnson & Johnson Private Limited Antiproliferative Drugs Revenue (US$, Mn), (2017-2022)

Table 75. Teva Pharmaceutical Industries Corporate Summary

Table 76. Teva Pharmaceutical Industries Antiproliferative Drugs Product Offerings

Table 77. Teva Pharmaceutical Industries Antiproliferative Drugs Revenue (US$, Mn), (2017-2022)

Table 78. Veloxis Pharmaceuticals Corporate Summary

Table 79. Veloxis Pharmaceuticals Antiproliferative Drugs Product Offerings

Table 80. Veloxis Pharmaceuticals Antiproliferative Drugs Revenue (US$, Mn), (2017-2022)

Table 81. Eli Lilly and Company Corporate Summary

Table 82. Eli Lilly and Company Antiproliferative Drugs Product Offerings

Table 83. Eli Lilly and Company Antiproliferative Drugs Revenue (US$, Mn), (2017-2022)

Table 84. Lupin Corporate Summary

Table 85. Lupin Antiproliferative Drugs Product Offerings

Table 86. Lupin Antiproliferative Drugs Revenue (US$, Mn), (2017-2022)

Table 87. AstraZeneca Corporate Summary

Table 88. AstraZeneca Antiproliferative Drugs Product Offerings

Table 89. AstraZeneca Antiproliferative Drugs Revenue (US$, Mn), (2017-2022)

List of Figures

Figure 1. Antiproliferative Drugs Segment by Type in 2021

Figure 2. Antiproliferative Drugs Segment by Application in 2021

Figure 3. Global Antiproliferative Drugs Market Overview: 2021

Figure 4. Key Caveats

Figure 5. Global Antiproliferative Drugs Market Size: 2021 VS 2028 (US$, Mn)

Figure 6. Global Antiproliferative Drugs Revenue, 2017-2028 (US$, Mn)

Figure 7. The Top 3 and 5 Players Market Share by Antiproliferative Drugs Revenue in 2021

Figure 8. By Type - Global Antiproliferative Drugs Revenue Market Share, 2017-2028

Figure 9. By Application - Global Antiproliferative Drugs Revenue Market Share, 2017-2028

Figure 10. By Region - Global Antiproliferative Drugs Revenue Market Share, 2017-2028

Figure 11. By Country - North America Antiproliferative Drugs Revenue Market Share, 2017-2028

Figure 12. US Antiproliferative Drugs Revenue, (US$, Mn), 2017-2028

Figure 13. Canada Antiproliferative Drugs Revenue, (US$, Mn), 2017-2028

Figure 14. Mexico Antiproliferative Drugs Revenue, (US$, Mn), 2017-2028

Figure 15. By Country - Europe Antiproliferative Drugs Revenue Market Share, 2017-2028

Figure 16. Germany Antiproliferative Drugs Revenue, (US$, Mn), 2017-2028

Figure 17. France Antiproliferative Drugs Revenue, (US$, Mn), 2017-2028

Figure 18. U.K. Antiproliferative Drugs Revenue, (US$, Mn), 2017-2028

Figure 19. Italy Antiproliferative Drugs Revenue, (US$, Mn), 2017-2028

Figure 20. Russia Antiproliferative Drugs Revenue, (US$, Mn), 2017-2028

Figure 21. Nordic Countries Antiproliferative Drugs Revenue, (US$, Mn), 2017-2028

Figure 22. Benelux Antiproliferative Drugs Revenue, (US$, Mn), 2017-2028

Figure 23. By Region - Asia Antiproliferative Drugs Revenue Market Share, 2017-2028

Figure 24. China Antiproliferative Drugs Revenue, (US$, Mn), 2017-2028

Figure 25. Japan Antiproliferative Drugs Revenue, (US$, Mn), 2017-2028

Figure 26. South Korea Antiproliferative Drugs Revenue, (US$, Mn), 2017-2028

Figure 27. Southeast Asia Antiproliferative Drugs Revenue, (US$, Mn), 2017-2028

Figure 28. India Antiproliferative Drugs Revenue, (US$, Mn), 2017-2028

Figure 29. By Country - South America Antiproliferative Drugs Revenue Market Share, 2017-2028

Figure 30. Brazil Antiproliferative Drugs Revenue, (US$, Mn), 2017-2028

Figure 31. Argentina Antiproliferative Drugs Revenue, (US$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Antiproliferative Drugs Revenue Market Share, 2017-2028

Figure 33. Turkey Antiproliferative Drugs Revenue, (US$, Mn), 2017-2028

Figure 34. Israel Antiproliferative Drugs Revenue, (US$, Mn), 2017-2028

Figure 35. Saudi Arabia Antiproliferative Drugs Revenue, (US$, Mn), 2017-2028

Figure 36. UAE Antiproliferative Drugs Revenue, (US$, Mn), 2017-2028

Figure 37. Accord Healthcare Antiproliferative Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)

Figure 38. F. Hoffmann-La Roche Antiproliferative Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)

Figure 39. Novartis AG Antiproliferative Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)

Figure 40. Mylan N.V. Antiproliferative Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)

Figure 41. Astellas Pharma Antiproliferative Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)

Figure 42. Pfizer Antiproliferative Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)

Figure 43. Glenmark Pharmaceuticals Limited Antiproliferative Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)

Figure 44. Zydus Cadila Antiproliferative Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)

Figure 45. Bristol-Myers Squibb Company Antiproliferative Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)

Figure 46. GlaxoSmithKline Antiproliferative Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)

Figure 47. Sanofi Antiproliferative Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)

Figure 48. Allergan Antiproliferative Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)

Figure 49. AbbVie Antiproliferative Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)

Figure 50. Cipla Antiproliferative Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)

Figure 51. Johnson & Johnson Private Limited Antiproliferative Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)

Figure 52. Teva Pharmaceutical Industries Antiproliferative Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)

Figure 53. Veloxis Pharmaceuticals Antiproliferative Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)

Figure 54. Eli Lilly and Company Antiproliferative Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)

Figure 55. Lupin Antiproliferative Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)

Figure 56. AstraZeneca Antiproliferative Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)

Methodology/Research Approach

This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.

Research Programs/Design

Historical Data (2015-2019)	Industry Trends Competitive Landscape By Company Expansion Mergers and Acquisitions Market Segment by Type by Application By Regions/ Geography	Value Status and Outlook Value for Major Players Market Share Growth Rate Present Situation Analysis Value Market Share Growth Rate Present Situation Analysis
Influencing Factors	Market Environment Government Policy Technological Changes Market Risks	Market Drivers Growing Demand of Downstream Reduction in Cost
Market Forecast (2021-2026)	Overall Size by Type by Application By Regions/Geography	Key Data (Value) Market Share Growth Rate CAGR (2021-2026)

Market Size Estimation

Top-down and bottom-up approaches are used to validate the global Voluntary Carbon Offset market size market and estimate the market size for Company, regions segments, product segments and Application (end users).

The market estimations in this report are based on the marketed sale price of Voluntary Carbon Offset (excluding any discounts provided by the player, distributor, wholesaler or traders). The percentage splits, market share, and breakdowns of the product segments are derived on the basis of weights assigned to each of the segments on the basis of their utilization rate and average sale price. The regional splits of the overall Voluntary Carbon Offset market and its sub-segments are based on the percentage adoption or utilization of the given product in the respective region or country.

Major Company in the market is identified through secondary research and their market revenues determined through primary and secondary research. Secondary research included the research of the annual and financial reports of the top Company; whereas, primary research included extensive interviews of key opinion leaders and industry experts such as experienced front-line staff, directors, CEOs and marketing executives. The percentage splits, market share, Growth Rate and breakdowns of the product markets are determined through using secondary sources and verified through the primary sources.

All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or other factors are not accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Market Intellix and presented in this report

The following figure shows an illustrative representation of the overall market size estimation process used for this study.

Market Breakdown and Data Triangulation

After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation, extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.

Data Source

Secondary Sources

Secondary sources include such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, etc. This research study involves the usage of widespread secondary sources, directories, databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), and TRADING ECONOMICS, and News Network, statista, Federal Reserve Economic Data, annual reports, BIS Statistics, ICIS; company house documents; CAS(American Chemical Society); investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and Hospitals study of the Voluntary Carbon Offset market. It was also used to obtain important information about the top companies, market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives.

Market Size	Segmental value Geographic Penetration Product Adoption Rate for Different market	Journals, Websites, and Press Releases Annual Reports and SEC Filings Company Websites and Press Releases Public and Paid Databases Market Intellix Data Repository
Market Position of Top Company	Product Financials Geographic value Mix Total Company value Business/Segmental value Mix
Qualitative Analysis	Influence Factors Market Potential Market Risks and Opportunities Industry Trends Geographical Features Government Policies	Company Websites and Press Releases Public and Paid Databases Annual Reports Industry Associations Market Intellix Data Repository

Primary Sources

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product Company (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.

The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end use (product buyers), and related key executives from various key companies and organizations operating in the global market.

Primary research was conducted to identify segmentation Type, product price range, product Application, key Company, raw materials supply and the downstream demand, industry status and outlook, and key market dynamics such as risks, influence factors, opportunities, market barriers, industry trends, and key player strategies.

Key Executives Interviewed

Key Data Information from Primary Sources

Primary Sources	Parameters	Key Data
Market Segments(by Application, by Type)	Value by Type Status and Forecast Value by Application Value by Regions, Status and Forecast (2021-2026)	Value Market Share by Type Value Growth Rate by Type Value by Application Percentage and Growth Rate by Application Value Growth Rate and Market Share by Regions Market Size Status and Forecast (2021-2026)
Total Market	Overall Size, Status and Forecast	Market Size Status and Forecast (2021-2026)